PALB2 and triple-negative breast carcinoma: In this report, we characterized an intragenic duplication breakpoint of <i>PALB2</i> to determine its pathogenicity significance.<h4>Methods</h4>A 52-year-old female with triple-negative breast cancer was diagnosed with a novel <i>PALB2</i> LGR.